JP7566008B2 - イミダゾピリジノン化合物又はその塩の結晶 - Google Patents

イミダゾピリジノン化合物又はその塩の結晶 Download PDF

Info

Publication number
JP7566008B2
JP7566008B2 JP2022507231A JP2022507231A JP7566008B2 JP 7566008 B2 JP7566008 B2 JP 7566008B2 JP 2022507231 A JP2022507231 A JP 2022507231A JP 2022507231 A JP2022507231 A JP 2022507231A JP 7566008 B2 JP7566008 B2 JP 7566008B2
Authority
JP
Japan
Prior art keywords
peaks
compound
crystal
crystals
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022507231A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021182490A1 (https=
Inventor
秀樹 竹内
喜朗 木島
彰博 森山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of JPWO2021182490A1 publication Critical patent/JPWO2021182490A1/ja
Application granted granted Critical
Publication of JP7566008B2 publication Critical patent/JP7566008B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022507231A 2020-03-11 2021-03-10 イミダゾピリジノン化合物又はその塩の結晶 Active JP7566008B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020041453 2020-03-11
JP2020041453 2020-03-11
PCT/JP2021/009405 WO2021182490A1 (ja) 2020-03-11 2021-03-10 イミダゾピリジノン化合物又はその塩の結晶

Publications (2)

Publication Number Publication Date
JPWO2021182490A1 JPWO2021182490A1 (https=) 2021-09-16
JP7566008B2 true JP7566008B2 (ja) 2024-10-11

Family

ID=77672382

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507231A Active JP7566008B2 (ja) 2020-03-11 2021-03-10 イミダゾピリジノン化合物又はその塩の結晶

Country Status (8)

Country Link
US (1) US20230167108A1 (https=)
EP (1) EP4091670A4 (https=)
JP (1) JP7566008B2 (https=)
KR (1) KR20220152276A (https=)
CN (1) CN115279761B (https=)
AU (1) AU2021233433A1 (https=)
CA (1) CA3169000A1 (https=)
WO (1) WO2021182490A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021143176A (ja) * 2020-03-12 2021-09-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521445A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ
JP2010535855A (ja) 2007-08-10 2010-11-25 クリスタルゲノミクス、インク． ピリジン誘導体およびその使用方法
JP2013508464A (ja) 2009-11-06 2013-03-07 エアーピオ セラピューティクス インコーポレイテッド 大腸炎を治療するための組成物および方法
WO2014181813A1 (ja) 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
WO2020054788A1 (ja) 2018-09-13 2020-03-19 キッセイ薬品工業株式会社 イミダゾピリジノン化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
CA2698071A1 (en) 2007-08-27 2009-03-05 Wyeth Llc Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
EP2285375B1 (en) 2008-05-08 2013-04-10 Merck Sharp & Dohme Corp. spiroazaindole compounds as HIF propylhydroxylase inhibitors
SI2455381T1 (sl) * 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521445A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ
JP2010535855A (ja) 2007-08-10 2010-11-25 クリスタルゲノミクス、インク． ピリジン誘導体およびその使用方法
JP2013508464A (ja) 2009-11-06 2013-03-07 エアーピオ セラピューティクス インコーポレイテッド 大腸炎を治療するための組成物および方法
WO2014181813A1 (ja) 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
WO2020054788A1 (ja) 2018-09-13 2020-03-19 キッセイ薬品工業株式会社 イミダゾピリジノン化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021143176A (ja) * 2020-03-12 2021-09-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法
JP7654426B2 (ja) 2020-03-12 2025-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法

Also Published As

Publication number Publication date
US20230167108A1 (en) 2023-06-01
JPWO2021182490A1 (https=) 2021-09-16
AU2021233433A1 (en) 2022-10-06
KR20220152276A (ko) 2022-11-15
CN115279761A (zh) 2022-11-01
CA3169000A1 (en) 2021-09-16
EP4091670A1 (en) 2022-11-23
CN115279761B (zh) 2025-03-14
WO2021182490A1 (ja) 2021-09-16
EP4091670A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
CN114907387B (zh) 嘧啶并吡咯类kras抑制剂及其制备方法与应用
CN112724145A (zh) 用于抑制shp2活性的吡嗪衍生物
CN114057771B (zh) 大环化合物及其制备方法和应用
CN117800989A (zh) 一类含环外双键、多取代甲基醚结构的化合物及其应用
KR20240004634A (ko) 삼환식 유비퀴틴 특이적 프로테아제 1 억제제 및 이의 용도
JP2017528491A (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
TW201731841A (zh) 6‐芳基或6‐異芳基‐4‐嗎啉‐4‐芳基‐吡啶‐2‐酮化合物
JP2023504866A (ja) 大環構造を有するフッ素含有複素環誘導体およびその用途
CN112778302A (zh) 一种kras g12c抑制剂化合物及其用途
JP2019512459A (ja) ７員環化合物、その調製方法、その医薬組成物、およびその使用
CN112047943A (zh) 一种选择性抑制激酶化合物及其用途
JP7566008B2 (ja) イミダゾピリジノン化合物又はその塩の結晶
CN118359589A (zh) Cdk12降解抑制剂及其用途
WO2019189766A1 (ja) 新規ビアリールアミド誘導体
CN109666022B (zh) 三氮唑衍生物及其制备方法和用途
HK40083277A (en) Crystal of imidazopyridinone compound or salt thereof
CN115244054B (zh) 次黄嘌呤化合物的晶体
KR102959367B1 (ko) Ep4 길항제 화합물, 이의 염, 다형체 및 용도
WO2019233366A1 (zh) 选择性a 2a受体拮抗剂
TW200418853A (en) Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
JP7819298B2 (ja) Ｅｐ４拮抗剤化合物及びその塩、結晶多形並びに使用
CN120842220A (zh) 芳基酰胺类化合物及其应用
CN120208988A (zh) 环状化合物及其药物组合物和应用
WO2024114765A9 (zh) 苯并吡喃酮类化合物、其制备方法及其应用
CN121108109A (zh) 一种靶向alk蛋白的protac化合物及其抗肿瘤应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241001

R150 Certificate of patent or registration of utility model

Ref document number: 7566008

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150